Publications – XENOTHERA

~~Related~~
scientific papers

2025

2024

2023

2022

2021

2020

2019

2017

2016

2015

2014

2025

October, 2025

FIPO23: A First-in-Human Trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb) Targeting Multiple Tumor Antigens in Advanced Solid Tumors

Jaafar Bennouna, Françoise Shneiker, Jean-Yves Blay, Mehdi Brahmi, Firas Bassissi, R. Ratta, Jean-Pierre Delord, C. Gomez Roca, C. Jungels, Ahmad Awada

September, 2025

XON9—A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma

Pierre-Joseph Royer, Carine Ciron, Gwenaelle Evanno, Ophélie Dauphouy, Juliette Rousse, George Graur, Odile Duvaux and Firas Bassissi

June, 2025

PALT trial : First in class glyco-humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL). Abstract ICML 2025

Gandhi Damaj, Françoise Shneiker, Emmanuel Bachy, Antonio Pinto, Firas Bassissi, Olivier Tournilhac and Pier Luigi Zinzani

June, 2025

LIS22: An Effective Multimodal Polyclonal Antibody Targeting T-Cell Malignancies. Abstract ICML 2025

Carine Ciron, Ophélie Dauphouy, Sadja Belkhelouat, Pierre-Joseph Royer, Juliette Rousse, Françoise Shneiker, Odile Duvaux, Nicolas Ortonne and Firas Bassissi

April, 2025

XON11, a novel multi-target antibody in pancreas cancer

Carine Ciron, Ophelie Dauphouy, Pierre-Joseph Royer, Gwenaelle Evanno, George Graur, Odile Duvaux, Firas Bassissi

April, 2025

XON7, a new emerging multitarget immunotherapy against metastatic soft tissue sarcomas

Ciron Carine, Gwenaelle Evanno, Pierre-Joseph Royer, Odile Duvaux, Firas Bassissi

April, 2025

Suppression of triple-negative breast cancer metastasis by a new glyco-humanized polyclonal antibody

Carine Ciron, Ophélie Dauphouy, Pierre-Joseph Royer, Pierre Morice, Odile Duvaux, Firas Bassissi

April, 2025

Characterization of XON9, an effective glyco-humanized polyclonal antibody against hepatocarcinoma

Pierre-Joseph Royer, Carine Ciron, Ophelie Dauphouy, George Graur, Odile Duvaux, Firas Bassissi

2024

June, 2024

The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors

Jaafar Bennouna, Françoise Shneiker, Jean-Yves Blay, Ahmad Awada, Firas Bassissi, Raffaele Ratta, Jean-Pierre Delord

April, 2024

XON7, a new Glyco-Humanized Polyclonal Antibody, first in class immunotherapy against several solid tumors

Carine Ciron, Gwenaelle Evanno, Pierre Morice, Pierre-Joseph Royer, Françoise Shneiker, Odile Duvaux, Bernard Vanhove, Firas Bassissi

April, 2024

XON27, a novel and potent immunotherapy against hematologic malignancies

Carine Ciron, Pierre Morice, Françoise Shneiker, Odile Duvaux, Firas Bassissi

April, 2024

LIS22, a first in class polyclonal antibody immunotherapy against T Cell blood cancers

Carine Ciron, Ophelie Dauphouy, Juliette Rousse, Pierre-Joseph Royer, Pierre Morice, Gwenaelle Evanno, Françoise Shneiker, Odile Duvaux, Firas Bassissi

February, 2024

First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation

Ondrej Viklicky, Janka Slatinska, Libor Janousek, Juliette Rousse, Pierre-Joseph Royer, Pierre-Louis Toutain, Emanuele Cozzi, Cesare Galli, Gwenaelle Evanno, Odile Duvaux, Jean-Marie Bach, Jean-Paul Soulillou, Magali Giral, Bernard Vanhove, Gilles Blancho

January, 2024

Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors

Carine Ciron, Pierre Morice, Juliette Rousse, Patrice Roy, Pierre-Joseph Royer, Olivier Gauthier, Sophie Brouard, Odile Duvaux, Firas Bassissi, Bernard Vanhove

2023

December, 2023

New polyclonal antibodies, inhibit selectively tumor growth and invasion and synergize with immune checkpoint inhibitors

Carine Ciron, Pierre Morice, Juliette Rousse, Patrice Roy, Pierre-Joseph Royer, Olivier Gauthier, Sophie Brouard, Odile Duvaux, Firas Bassissi, Bernard Vanhove

October, 2023

XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants

Garyfallia Poulakou, Pierre-Joseph Royer, Nikolai Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez

2022

November 15, 2021

XAV19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

B.Vanhove, S.Marot, R-T.So,B.Gaborit, G.Evanno, I.Malet, G.Lafrogne, E.Mevel, C.Ciron, P-J.Royer, E.Lheriteau, F.Raffi, R.Bruzzone, C-K.Pun Mok, O.Duvaux, A-G.Marcelin, V.Calvez

September, 2022

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation

Juliette Rousse 1*, Pierre-Joseph Royer 1, Gwenaëlle Evanno 1, Elsa Lheriteau 1, Carine Ciron 1, Apolline Salama 5*, Françoise Shneiker 1, Roberto Duchi 2*, Andrea Perota 2, Cesare Galli 2, Emmanuele Cozzi 4*, Gilles Blancho 5, Odile Duvaux 1, Sophie Brouard 5, Jean-Paul Soulillou 5 Jean-Marie Bach 3* and Bernard Vanhove

¹Xenothera, Nantes, France
²Avantea, Laboratorio di Tecnologie della Riproduzione, Cremona, Italy
³niris, INRAE, IECM, USC 1383, 44300 Nantes, France
⁴ Transplantation Immunology Unit, Padua University Hospital, Padova, Italy
⁵Nantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, F-44000 Nantes, France

2021

November 15, 2021

XAV19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

B.Vanhove, S.Marot, R-T.So,B.Gaborit, G.Evanno, I.Malet, G.Lafrogne, E.Mevel, C.Ciron, P-J.Royer, E.Lheriteau, F.Raffi, R.Bruzzone, C-K.Pun Mok, O.Duvaux, A-G.Marcelin, V.Calvez

April 5, 2021

XAV19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants

B.Vanhove, S.Marot, B.Gaborit, G.Evanno, I.Malet, C.Ciron, P-J.Royer, E.Lheriteau, S.Denié, F.Raffi, O.Duvaux, A-G.Marcelin, V.Calvez

2020

July 25, 2020

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

Vanhove, Duvaux et al, Xenothera.

2019

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte Immunoglobulins shows selective depletion of T lymphocytes versus Treg and Breg

Rousse et al, ESOT 2019, Copenhagen, Denmark

2019

Anti-Neu5Gc responses in kidney allograft recipients after treatment with Rabbit Anti-Thymocyte Globulins.

Rousse et al, ESOT 2019, Copenhaguen, Denmark

2019

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte immunoglobulins efficiently delay skin graft rejection in non-human primate

Ciron et al, ESOT 2019, Copenhagen, Denmark

2019

Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients

Rousse et al, Eur J Clin Invest. 2019. Apr;49 (4)

2017

Anti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with Anti-Thymocyte Globulin

Salama et al

2017

Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs

Salama et al

2016

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Reynard et al, PLoS One

2015

Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival

Couvrat-Desvergnes et al, J Clin Invest

2015

Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.

Salama et al, Xenotransplantation

2014

Long-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts

Scobie et al, J Immunol